Premium
P3‐273: Discovery of novel, potent BACE inhibitors with central activity for the treatment of Alzheimer's disease
Author(s) -
Hyde Lynn A.,
Leach Prescott T.,
Zhang Qi,
Terracina Giuseppe,
Werner Bonnie J.,
Hodgson Robert A.,
Cantu Cinzia,
Chen Xia,
Chen Maxine,
Misiaszek Jeffrey,
Wu Yusheng,
Babu Suresh,
Guo Tao,
Tadesse Dawit,
Scott Jack,
Li Wei,
Zhang Lili,
Parker Eric M.,
Stamford Andrew W.,
Kennedy Matthew E.
Publication year - 2010
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2010.05.1773
Subject(s) - in vivo , amyloid precursor protein secretase , genetically modified mouse , pharmacology , amyloid precursor protein , chemistry , ex vivo , transgene , enzyme , senile plaques , gamma secretase , in vitro , alzheimer's disease , biochemistry , disease , medicine , biology , gene , pathology , microbiology and biotechnology
Lynn A. Hyde, Prescott T. Leach, Qi Zhang, Giuseppe Terracina, Bonnie J. Werner, Robert A. Hodgson, Cinzia Cantu, Xia Chen, Maxine Chen, Jeffrey Misiaszek, Yusheng Wu, Suresh Babu, Tao Guo, Dawit Tadesse, Jack Scott, Wei Li, Lili Zhang, Eric M. Parker, Andrew W. Stamford, Matthew E. Kennedy, Merck Research Laboratories, Kenilworth, NJ, USA; Ligand Pharmaceuticals, Inc, Cranbury, NJ, USA. Contact e-mail: lynn.hyde@spcorp.com